• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA approves Abiomed Impella RP Flex with SmartAssist for treating right heart failure

FDA approves Abiomed Impella RP Flex with SmartAssist for treating right heart failure

October 31, 2022 By Sean Whooley

Abiomed Impella RP Flex with SmartAssist
The Impella RP Flex with SmartAssist. [Image from Abiomed]
Abiomed (Nasdaq:ABMD) announced today that the FDA granted its Impella RP Flex with SmartAssist pre-market approval (PMA).

Danvers, Massachusetts-based Abiomed designed the Impella RP Flex with SmartAssist to treat right heart failure. It does so for up to 14 days. The company intends to introduce Impella RP Flex in the U.S. through a controlled launch this quarter.

The FDA indicated Impella RP Flex with SmartAssist for providing temporary right ventricular support for up to 14 days in patients with a body surface area ≥1.5 m2. These patients develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.

Patients receive the Impella RP Flex via implant into the internal jugular (IJ) vein. This enables patient mobility, according to a news release. The heart pump also features dual-sensor technology for optimizing patient management, Abiomed said.

Impella RP includes the world’s smallest percutaneous right heart mechanical circulatory support (MCS) technologies, Abiomed said. The company designed these technologies to help patients achieve native heart recovery. They don’t require extracorporeal blood circulation.

Abiomed said its MCS technologies represent the only such offerings with FDA PMA indications for treating right heart failure.

“Impella RP Flex demonstrates Abiomed’s ongoing commitment to improving patient survival and achieving native heart recovery,” said Dr. Mark B. Anderson, chair of the department of cardiac surgery and cardiothoracic surgeon at the Heart and Vascular Hospital at HUMC/Hackensack Meridian Health.

About Impella RP Flex with SmartAssist

Impella RP Flex features single venous access through the IJ vein with an 11 French (Fr) indwelling catheter. This facilitates patient mobility, Abiomed said.

Additionally, it designed the platform with a flexible cannula advanced over an extra-support guidewire. The company said it enables both ease of insertion and pump delivery.

The SmartAssist dual-sensor technology combines with Impella Connect to deliver advanced metrics for pump management and weaning. Abiomed also developed a heparin-free purge to simplify patient anticoagulant management. Sodium bicarbonate is used where heparin is of concern due to heparin intolerance or bleeding.

Study data demonstrated a significantly higher survival rate in those who received Impella RP support compared to those who received delayed right-heart support. Within 48 hours of cardiogenic shock onset, Impella RP patients registered a 73% survival rate. Those who received delayed support survived at just a 14% clip.

“The complexity of right ventricular failure has resulted in patients being underdiagnosed and undertreated,” said Dr. Robert Salazar, an interventional cardiologist and director of cardiovascular research at Kingwood Medical Center. “Impella RP Flex is a novel tool that gives physicians the flexibility to treat this challenging patient population.”

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Catheters, Featured, Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA), Regulatory/Compliance, Structural Heart Tagged With: Abiomed

More recent news

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy